In October 2016 BioLeap, LLC was acquired by Pensylvania company MetaLeaps, LLC. a computational fragment-based drug design (CFBDD) technology that takes into account the free energy of interactions between (i) proteins and fragments or molecules and (ii) free water molecules and the target, in a practical timeframe - enabling high predictive power -typically, less than 100 molecules need to be synthesized to achieve an optimized lead. BioLeap, LLC, had been a drug design and discovery company, identifying and optimizing lead compounds using its proprietary technology platform. The firm's in-silico platform predicts fragment-protein binding information; and had enabled drug designers efficiently to create new and improved drug molecule candidates. Serving pharmaceutical and agricultural chemical companies. the companys design platform supported the prediction of binding affinity based on thermodynamic principles, giving drug designers new insights to create non-obvious molecules and improve existing molecules.
